FOCUS on New Drug Approvals. Yesterday the FDA approved SpringWorks Therapeutics‘ Mirdametinib (PD-325901) for the treatment of patients with neurofibromatosis type 1 with symptomatic plexiform neurofibromas
Focus on drug discovery failure. Development of Risvodetinib for Parkinson’s disease was halted following disappointing Phase II results. The drug, which is a potent, brain-penetrant c-Abl
Focus on New Drug Approvals. The FDA approved Vertex Pharmaceutical’s Suzetrigine (VX-548) for the treatment of moderate to severe acute pain in adults. Suzetrigine is a
Focus on elimination of senescent cancer cells. Researchers at the Netherlands Cancer Institute just reported in PNAS that SLC25A23 (involved in mitochondrial transmembrane transport) is a
Science’s 2024 “Breakthrough of the Year” is Gilead’s drug Lenacapavir, an injectable drug that demonstrated remarkable success at preventing HIV infection with one shot every 6
Focus on Drug Approvals. This week the FDA approved Ensartinib for ALK-positive locally advanced or metastatic non-small cell lung cancer. Ensartinib is a potent and specific
Website Created by Advanta Advertising LLC.
